Achievement of therapeutic targets in patients with diabetes and chronic kidney disease: Insights from the Associazione Medici Diabetologi Annals initiative

Nephrology Dialysis Transplantation

Volumn 30, Issue 9, 2015, Pages 1526-1533

  De Cosmo, Salvatore ^a   Viazzi, Francesca ^b   Pacilli, Antonio ^a   Giorda, Carlo ^c   Ceriello, Antonio ^d   Gentile, Sandro ^e   Russo, Giuseppina ^f   Rossi, Maria Chiara ^g   Nicolucci, Antonio ^g   Guida, Pietro ^h   Di Bartolo, Paolo ⁱ   Pontremoli, Roberto ^b  

^a CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c ASL Turin 5   (Italy)

^d INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^e Interdepartmental Research Center in Health Management and Innovation in Healthcare   (Italy)

^f UNIVERSITY OF MESSINA   (Italy)

^g Consorzio Mario Negri Sud ^*  (Italy)

^h Statistical Consultant for Associazione Medici Diabetologi (AMD)   (Italy)

ⁱ Department of Vascular Medicine   (Italy)

Author keywords

Antihypertensive treatment; arterial hypertension; cardiovascular risk factors; diabetic nephropathy; hypercholesterolaemia

Indexed keywords

ALBUMIN; CREATININE; GLUCOSE; HEMOGLOBIN A1C; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ANTIHYPERTENSIVE AGENT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

AGED; ALBUMINURIA; ARTICLE; BLOOD LEVEL; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; BODY MASS; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE DURATION; FEMALE; GLYCEMIC CONTROL; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SEX DIFFERENCE; BLOOD; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; GLUCOSE BLOOD LEVEL; METABOLISM; PATHOPHYSIOLOGY; RENAL INSUFFICIENCY, CHRONIC;

AGED; ALBUMINURIA; ANTIHYPERTENSIVE AGENTS; BLOOD GLUCOSE; BLOOD PRESSURE; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; RENAL INSUFFICIENCY, CHRONIC;

EID: 84940657013     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfv101     Document Type: Article

References (34)

1. IDF Diabetes Atlas UpDate 2013. Available at: http://www.idf.org/diabetesatlas/6e/upDate2013
2. Whiting DR, Guariguata L,Weil C et al. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 2011; 94: 311-321
3. Williams ME. Diabetic CKD/ESRD 2010: a progress report Semin Dial 2010; 23: 129-133
4. US Renal Data System. USRDS 2013 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. BethesDa, MD: US Renal Data System, 2013
5. Fox CS, Matsushita K, Wooward M et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet 2012; 380: 1662-1673
6. Ninomiya T, Perkovic V, De Galan BE et al. Albuminuria and kidney function inDepenDently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol 2009; 20: 1813-1821
7. Afkarian M, Sachs MC, Kestenbaum B et al. Kidney disease and increased mortality risk in type 2 diabetes. J Am Soc Nephrol 2009; 24: 302-308
8. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 1998; 352: 837-853
9. Ray KK, Seshasai SR, Wijesuriya S et al. Effect of intensive control of glucose on cardiovascular outcomes and Death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 2009; 373: 1765-1772
10. Turnbull FM, Abraira C, AnDerson RJ et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 2009; 52: 2288-2298
11. KellyTN, BazzanoLA, FonsecaVAet al. Systematic review: glucose control and cardiovascular disease in type 2 diabetes. Ann Intern Med 2009; 151: 394-403
12. Cholesterol Treatment Trialists' (CTT) CollaboratorsKearney PM, Blackwell L, Collins R et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008; 371: 117-125
13. Baigent C, Landray MJ, Reith C et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011; 377: 2181-2192
14. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703-713
15. Adler AI, Stratton IM, Neil HA et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000; 321: 412-419
16. Rönnback M, Isomaa B, Fagerudd J et al. Complex relationship between blood pressure and mortality in type 2 diabetic patients. Follow-up of the Botnia Study. Hypertension 2006; 47: 168-173
17. GæDe P, Lund-AnDersen H, Parving HH et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008; 358: 580-591
18. Shurraw S, Hemmelgarn B, LinMet al. Association between glycemic control and adverse outcomes in people with diabetes mellitus and chronic kidney disease: a population-based cohort study. Arch Intern Med 2011; 171: 1920-1927
19. American Diabetes Association. StanDards of Medical Care in Diabetes 2014. Diabetes Care 2014; 37(Suppl 1): S14-S80
20. Associazione Medici Diabetologi and Società Italiana di Diabetologia. StanDard Italiani Per La Cura Del Diabete Mellito, 2014. http://www. stanDarditaliani.it/skin/www.stanDarditaliani.it/pdf/STANDARD-2014-May28.pdf
21. Mancia G, Fagard R, Narkiewicz K et al. ESH/ESC GuiDelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society ofHypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31: 1281-1357
22. KidneyDisease: ImprovingGlobalOutcomes (KDIGO) Blood PressureWork Group. KDIGO Clinical Practice GuiDeline for the Management of Blood Pressure in chronic kidney disease. Kidney Int 2012; 2 (Suppl): 337-414
23. Ko KD, Kim BH, Park SM et al. What are patient factors associated with the quality of diabetes care Results from the Korean National Health and Nutrition Examination Survey. BMC Public Health 2012; 12: 689
24. Fraser SDS, RoDerick PJ, Mcintyre NJ et al. Suboptimal blood pressure control in chronic kidney disease stage 3: baseline Data from a cohort study in primary care. BMC Family Practice 2013; 14: 88
25. Cadwell B, Gregg EW, Engelgau MM et al. Improvements in diabetes processes of care and intermediate outcomes: United States, 1988-2002. Ann Intern Med 2006; 144: 465-474
26. CasagranDe SS, Fradkin JE, SayDah SH et al. The prevalence of meeting A1c, Blood pressure, and LDL goals among people with diabetes, 1988-2010. Diabetes Care 2013; 36: 2271-2279
27. Cheung BMY, Ong KL, Cherny SS et al. Diabetes prevalence and therapeutic target achievement in the United State, 1999 to 2006. Am J Med 2009; 122: 443-453
28. Ali MK, Bullard KM, Saaddine JB et al. Achievement of goals in U.S. diabetes care, 1999-2010. N Engl J Med 2013; 368: 1613-1624
29. Nicolucci A, Rossi MC, Arcangeli A et al. Four-year impact of a continuous quality improvement effort implemented by a network of diabetes outpatient clinics: the AMD-Annals initiative. Diabet Med 2010; 27: 1041-1048
30. Rossi MC, Lucisano G, Comaschi M et al. Quality of diabetes care predicts the Development of cardiovascular events: results of the AMD-QUASAR. Diabetes Care 2011; 34: 347-352
31. Rossi MC, Cristofaro MR, Gentile S et al. Sex disparities in the quality of diabetes care: biological and cultural factors may play a different role for different outcomes: a cross-sectional observational study from the AMD Annals initiative. Diabetes Care 2013; 36: 3162-3168
32. De Cosmo S, Rossi MC, Pellegrini F et al. Kidney dysfunction and related cardiovascular risk factors among patients with type 2 diabetes. Nephrol Dial Transplant 2014; 29: 657-662
33. Levey AS, Stevens LA, Schmid CH et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604-612
34. Kuznik A, MarDekian J. Trends in utilization of lipid-and blood pressurelowering agents and goal attainment among the U.S. diabetic population, 1999-2008. Cardiovasc Diabetol 2011; 10: 31